Covered bonds Special

European Secured Note: new dual recourse instrument

Table of contents:
Key points 1
European Secured Note: what is it? 2
ESN proposed structures 3
Key takeaways from ESN Investor Survey 4

Key points

- **What is in the name?** The European Secured Note (ESN) has been designed by the ECBC in response to the EU Green Paper on Building Capital Markets Union. **ESNs are designed to provide a funding instrument that sits between traditional covered bonds and high-quality securitisations.** The ECBC outlines two possible implementation structures for the ESN. The first is an on-balance sheet ESN (considered a covered bond look-alike), with a dynamic pool and dual recourse to the bank raising the funding. The second is an off-balance sheet dual recourse instrument with a static pool, which could provide capital relief as well as promote risk transfer and risk sharing.

- **What is needed for the instrument to develop?** For the ESN product to develop, the market would require a **standardised definition** of an SME or other underlying qualifying collateral, and these common quality and eligibility features should be implemented across Europe with the same criteria. ESNs should benefit from pan-European standards and favourable regulatory treatment. In our view, the **public supervision** of this product, **together with UCITS eligibility, will be crucial for market acceptability** as it would pave the way for favourable regulatory treatment (e.g. eligibility for LCR purposes, Solvency II, ECB and Bank of England repo, CRA III Regulation). **Transparency** of data is also key.

- **Rating agencies have commented on the proposals.** Fitch has said the on-balance sheet ESN could be rated under its existing ‘Covered Bonds Rating Criteria’ and the capital-relief format could be rated under its ‘Global Structured Finance Rating Criteria’. Depending on the available enhancement, Fitch would recognise this via a recovery uplift of up to two notches above the bank’s IDR, if it is in the investment grade range. DBRS also said it could rate both structures, but the methodology would depend on the structure detail, legal framework, collateral information and transparency and provision (or not) of guarantee.

- **Would investors buy ESNs?** ESN could appeal to investors while covered bond yields are low. We ran a survey among real money investors to gauge investor sentiment on this product. Although some investors were hesitant to participate before more clarity is given on the product, we were able to gather a representative sample of responses. In terms of product design, respondents have a **preference for the on-balance sheet ESN structure** over the off-balance sheet structure. Homogeneous, easily comparable pools should be an essential feature of this product. Those investors preferring the off-balance sheet ESN said an external guarantee would not be necessary. **Preferential regulatory treatment** is crucial for the development of the product and **regulation enshrined in law** (at EU level) is preferred over contractual features. Other key factors in the investment decision will be **liquidity, index inclusion** and to a lesser extent rating. With regards to **pricing considerations**, a key driver for demand will be where the product will be placed between covered bonds and other asset classes.
European Secured Note: what is it?

The ECBC proposes to analyse the potential of a dual recourse funding instrument to respond to several priorities foreseen in the Green Paper namely (i) widening the investor base for SMEs and (ii) building sustainable high-quality securitisation.

While the ECBC proposal is broad in its comment and scope, it proposed two potential instruments aimed at improving the long-term funding for non-traditional collaterals such as SME or infrastructure loans:

- **On-balance sheet ESN (for funding purposes):** dual-recourse instrument using funding techniques derived from those used for covered bonds. As the name suggests, it is an on-balance sheet, dual-recourse obligation (benefiting from both the value of the collateral pool and a guarantee from the originator), backed by a dynamic pool of underlying obligations, and strengthened by a legal framework. For the on-balance sheet ESN to work, two elements are necessary: (i) a robust legal framework and (ii) a sufficiently high level of transparency regarding the asset pool.

- **Off-balance sheet ESN (for capital relief purposes):** are referred to as an instrument offering a degree of capital relief to the issuer through risk-transfer, whilst offering investors a more interesting yield proposition than the on-balance sheet alternative. The ECBC proposes that the static pool of SME assets be transferred to an off-balance sheet vehicle, where risk would be tranchéd and offered to investors. Public bodies could play a role in either investing or guaranteeing more subordinated risk positions. The equity tranche could be guaranteed by institutions such as the European Investment Bank Group (in particular the European Investment Fund), while the mezzanine tranche could be guaranteed by government-owned development banks (e.g. KfW, CDP, ICO, CDC) to encourage public involvement and the sponsoring of securitisation as a means of financing the real economy. Whilst senior notes would also be guaranteed by the originator. **This structure would closely resemble a securitisation** in the sense that the assets used in the pool would be transferred to an SPV via true sale or pledging using, for example, the collateral directive. As with traditional securitisation, the security would be tranchéd and each tranche would be secured by a portfolio of SME claims. Two basic general principles would need to be satisfied: 1) the originator must comply with the retention requirements by either retaining the junior tranche, 5% of each tranche, or by a 5% portfolio of similar risk on its balance sheet; and 2) public/international sponsors could play a role in investing or in guaranteeing some of the riskier tranches.

The ECBC notes that the ESN tool should be based on common eligibility criteria, definitions, risk parameters, data disclosure and IT solutions across European countries. The ECBC however, is clear in highlighting that traditional covered bonds have very precise quality features recognised in regulation and should not be watered down. They highlight authorities would need to establish a clear demarcation line between the traditional covered bond space and the potential use of dual recourse techniques for other kinds of assets as collateral.

In our view, the public supervision of this product, together with UCITS eligibility, will be crucial for market acceptability as it would pave the way for favourable regulatory treatment (e.g. eligibility for LCR purposes, Solvency II, ECB and Bank of England repo, CRA III Regulation).
ESN proposed structures

The ECBC proposes five possible structures for the on-balance sheet ESN and two possible structures for the capital relief ESN.

1. **Classic Direct On-Balance Issuance** (structure used for CBs in Germany, Spain, Denmark, Cyprus and Belgium), where the issuer of the bond is a bank and investors have a dual recourse to a bank and a segregated pool of assets. The assets are segregated through a pledge/register/specialised banking. Investors have a preferential claim to the segregated assets in the event of insolvency of the issuer. A potential disadvantage could be that the segregation of assets and swaps on-balance sheet may not be possible in certain jurisdictions due to the current legal setup.

2. **On-Balance Sheet Issuance with Separate Guarantor** (structure used for CBs in Italy, the Netherlands, the UK, Canada, NZ, Australia). In this structure, the bonds are issued by the bank whilst the assets are transferred to a separate legal entity that guarantees the bonds used. In this case, the legal framework should 1) allow the transfer of assets via true sale and 2) address potential limits on intra-company exposure. The guarantee provided by the SPV implies dual recourse.

3. **Issuance by SPV with True Sale of Assets from Bank** (similar to German ‘Refinanzierungsregister’ or Danish ‘Corporate Loan Refinancing Register’. The bank maintains the assets in a dynamic register but the segregated assets are truly sold to the SPV (dual recourse with assets no longer bail-in-able). The structure requires clear segregation of assets and debtors’ set-off rights need to be addressed in the event of the bank’s default.

4. **Issuance by SPV with Guarantee from Bank**: bonds are issued by the SPV that holds the assets (true sale). The bank is providing a guarantee on the bonds: there is no automatic dual recourse and most servicing activities are outsourced by the SPV to the bank.

5. **Multiple Bank Funding Structure**: bonds (or certificates) are issued by a bank or SPV in which the assets have been segregated via the registering of the assets in other entities. Issues about the transparency on all underlying assets and the bail-in topic should be addressed by the legal framework.

6. **ABS Guaranteed**: bonds are issued by the SPV according to the traditional securitisation structure with a first demand guarantee released by a supranational Guarantor on senior notes. Limited changes to the regulatory framework would be required but few guarantors would meet the criteria.

7. **ABS Backed by a Limited Recourse Loan**: bonds are issued by the SPV while the portfolio remains in the originator book. Pervasive changes to the legal framework are required in order to ensure the assets’ segregation and the proper functioning of the structure.
Key takeaways from ESN Investor Survey

Of the two main ESN proposals, most investors would prefer the on-balance sheet structure. Preferential regulatory treatment is crucial for the development of the product and regulation enshrined in law (at EU level) is preferred over contractual features. Other key factors in the investment decision will be liquidity, index inclusion and to a lesser extent rating. What is clear is that investors will require granular, transparent, easily identifiable pools. The ESN is viewed as a credit product and investors agreed in terms of relative value, they would price the on-balance sheet ESN somewhere between traditional covered bonds and senior unsecured notes.

In view of the upcoming ECBC Covered Bond & European Secured Note Roundtable to be held on 8 and 9 October in Milan, we conducted an investor survey over the past weeks to gauge investor sentiment on the ECBC’s European Secured Note (ESN) proposals. The questionnaire included 11 questions and was aimed at understanding which structure would be preferred, and which common criteria and features would be necessary to attract demand. We targeted real money investors, with 75% of respondents being asset managers. We specifically did not target many bank investors, because the large majority require regulatory treatment (LCR eligibility, preferential risk weighting) as sine qua non conditions to consider such a new product. Instead, we focussed on large asset managers who would have a more open approach to new dual recourse instruments, rather than pure traditional covered bond investors. This explains the relatively low participation of German investors. Although small (16 respondents), our sample is representative given that the investors that took part in our survey represent approximately €5 trillion AUM.

Lesson no. 1: Cheap funding and regulatory hurdles cited as the main reasons for low supply of dual-recourse instruments

Cheap senior unsecured funding and regulatory hurdles are cited as the main reasons for low supply of dual-recourse instruments. Lack of transparent pool information and comparability across asset classes was also cited as an important factor. Other reasons cited were the cost as well as the availability of overall cheap liquidity in the market. For issuers, the relative value of such a trade, when they could alternatively access TLTRO funding or ECB funding, issue covered bonds and cover the remainder of the balance sheet with deposits, means interest would be limited, especially whilst the ECB’s QE programme is running. Interestingly, both lack of investor demand and rating agency concerns were not seen as main concerns.

In your opinion, what have been the reasons for relatively low supply of dual-recourse instruments?

<table>
<thead>
<tr>
<th>Reason</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lack of investor demand</td>
<td>12.5%</td>
</tr>
<tr>
<td>Regulatory hurdles &lt;no preferential treatment&gt;</td>
<td>50.0%</td>
</tr>
<tr>
<td>Lack of eligible assets</td>
<td>18.8%</td>
</tr>
<tr>
<td>Lack of transparent pool and comparability across asset</td>
<td>43.8%</td>
</tr>
<tr>
<td>classes</td>
<td></td>
</tr>
<tr>
<td>Cheap senior unsecured funding</td>
<td>50.0%</td>
</tr>
<tr>
<td>Rating agency concerns</td>
<td>6.3%</td>
</tr>
</tbody>
</table>

Source: SG Cross Asset Research/Rates

07 October 2015
Lesson no. 2: Most investors seem to prefer the on-balance sheet ESN, with granular transparent collateral

With regards to product design, most of the respondents seem to favour the on-balance sheet ESN structure over the risk-sharing ESN format. However, many investors pointed out that the choice of structure would ultimately depend on the premium offered to traditional covered bond instruments to compensate for the additional complexity. For many investors, the capital-relief ESN structure very closely resembles securitisation, and, if faced with a choice between both, they would choose the securitisation route. For many, ABS enables in the best possible way investors to choose a risk return profile based on specific collateral pool via the tranching of the notes and the issuer can choose between a simple financing trade or a capital relief trade by deciding which part of the structure he wants to place with external investors. Ultimately, if regulators were to rethink their approach to penalising European ABS, the off balance sheet, capital-relief ESN initiative could become obsolete.

Which ESN structure would you prefer?

43.8% on-balance sheet ESN
31.3% risk-sharing ESN <using high-quality securitization techniques>
43.8% depends on premium offered to traditional covered bond instruments to compensate for additional complexity
0.0% no preference

To consider ESNs which type of collateral would you be interested in investing in?

73.3% high quality SME loans
60.0% high quality infrastructure loans
6.7% Other

In terms of collateral, investors seemed to have a preference for high quality SME loans, although infrastructure loans were also high on the list, as long as they are high quality, granular and easily identifiable, comparable pools.
Lesson no. 3: Regulation preferred over contractual features

Investors have a clear preference for the European Secured Note product to be enshrined in law, rather than based on contractual features. The overwhelming majority prefer regulation at EU level, rather than at national level. Furthermore, investors prefer easy to analyse, granular segregated pools. As such, the majority of respondents prefer homogenized cover pools (one asset type, one pool), with some investors asking for a limit per asset class to be defined.

To ensure recognition, marketability and liquidity of this instrument, collateral eligibility criteria should be developed. Where/How should the eligibility criteria be developed?

Lesson no. 4: Preferential regulatory treatment crucial for development of the ESN product

We targeted our survey mainly at real money investors and refrained from contacting many bank treasuries as for them, the sine qua non condition is preferential treatment (ECB repo-eligibility, LCR eligibility). What was interesting to note, was that with a large proportion of asset managers in our sample, most cited preferential risk-weighting, LCR eligibility and bail-in exemption as important features the ESN instrument would need to have. Other factors mentioned were index inclusion and rating. Liquidity is also key, as the ESN would need to be a sellable product.

Key factors, from a regulatory perspective, necessary for ESN development
Lesson no. 5: Granular, comparable, easily identifiable pools required

It is crucial to guarantee homogeneous and comparable characteristics, in order to facilitate lenders’ and investors’ due diligence and create the preconditions for a future pan-European cross-border SME financing landscape. Investors agree that for ESN product to take off, the collateral needs to be defined in terms of clear, key risk parameters. Regular, easily comparable investor reports are required. In terms of frequency, quarterly reports are the minimum but monthly asset reports would be privileged to monitor the dynamic nature of the cover pool. Respondents mentioned the availability of loan-by-loan level as helpful in their analysis, although stratified loan information tables would be enough.

For ESNs to gain market traction, the market would require harmonized levels of information and reporting to facilitate monitoring procedures and pricing rational. Would you require:

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loan by loan level data?</td>
<td>42.9%</td>
</tr>
<tr>
<td>Is stratified loan information tables enough?</td>
<td>35.7%</td>
</tr>
<tr>
<td>Monthly asset reports</td>
<td>42.9%</td>
</tr>
<tr>
<td>Quarterly investor reports</td>
<td>71.4%</td>
</tr>
<tr>
<td>Other</td>
<td>21.4%</td>
</tr>
</tbody>
</table>

Source: SG Cross Asset Research/Rates

The underlying loans (SMEs, infrastructure) are a more complex asset class and there is no common information on credit history and performance. As such, before the ESN initiatives come to fruition, investors highlighted the importance of having a centralised platform on which all data is uploaded and stressed the need for all pool information to be made public without restrictions on any institutional investor to access the data and reports.
Lesson no. 6: Relative value and liquidity of the product cited as the main investment drivers

As we mentioned earlier, liquidity in the secondary market will be a key driver for investors. For the on-balance sheet ESN, a key driver for demand will be where the product will be placed between covered bonds and senior unsecured bonds. When considering pricing, the responses were more muted with a slight preference for spreads to be closer to senior unsecured bonds, rather than closer to traditional covered bonds. But the pricing will ultimately depend on the quality and recovery expectation of the underlying collateral pool. If the ESN product is bail-in exempt, the product would be positioned closer to traditional covered bonds.

For the off-balance sheet, capital relief structure, the relative value of the product in relation to ABS will be a main investment driver. Absolute yield was also cited as a key determinant, particularly in the current low yield environment.

From a market perspective, what would be the main driver(s) to invest in this product?

<table>
<thead>
<tr>
<th>Relative Value</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>vs Sovereign/Agencies</td>
<td>33.3%</td>
</tr>
<tr>
<td>vs Credit Products</td>
<td>60.0%</td>
</tr>
<tr>
<td>vs ABS</td>
<td>53.3%</td>
</tr>
<tr>
<td>Absolute Yield</td>
<td>33.3%</td>
</tr>
<tr>
<td>Liquidity in the Secondary Market</td>
<td>60.0%</td>
</tr>
<tr>
<td>Other</td>
<td>6.7%</td>
</tr>
</tbody>
</table>

Source: SG Cross Asset Research/Rates
Lesson no. 7: external guarantee not necessary for development of capital-relief ESN

In the off-balance sheet, capital relief ESN structure, the ECBC proposes that public bodies could play a role in either investing or guaranteeing more subordinated risk positions.

For risk sharing ESN, the junior and equity tranches could be guaranteed by institutions (EIB and the European Investment Fund, KfW, CDP, ICO, CDC) to encourage public involvement and sponsoring of securitisation. However, when asked, most investors said an external guarantee is not necessary for the development of a capital-relief ESN.

Nevertheless, although not a necessary condition, many respondents cited the product would be enhanced with a guarantee.

Which investors would potentially buy European Secured Notes?

As can be seen in the chart below, the ESN product is seen as a credit product, with most portfolio managers saying that if this product were to be developed, they would go into credit index portfolios. The product would be interesting for total return portfolios and, less so for absolute yield portfolios or rates index portfolios. As was to be expected, few respondents mentioned the liquidity portfolios – this will depend on what regulatory treatment the instrument receives.

Within your institution, which PMs would potentially buy ESNs?

Source: SG Cross Asset Research/Rates
APPENDIX

ANALYST CERTIFICATION

The following named research analyst(s) hereby certifies or certify that (i) the views expressed in the research report accurately reflect his or her or their personal views about any and all of the subject securities or issuers and (ii) no part of his or her or their compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report: Cristina Costa

The analyst(s) who author research are employed by SG and its affiliates in locations, including but not limited to, Paris, London, New York, Dallas, Hong Kong, Tokyo, Bangalore, Mumbai, Frankfurt, Madrid, Milan, Seoul, Warsaw and Moscow.

SG CREDIT RESEARCH RATINGS

SG credit research may contain both a credit opinion of the company and market recommendations on individual bonds issued by the company and/or its Credit Default Swap.

Credit Opinion:

POSITIVE: Indicates expectations of a general improvement of the issuer’s credit quality over the next six to twelve months, with credit quality expected to be materially stronger by the end of the designated time horizon.

STABLE: Indicates expectations of a generally stable trend in the issuer’s credit quality over the next six to twelve months, with credit quality expected to be essentially unchanged by the end of the designated time horizon.

NEGATIVE: Indicates expectations of a general deterioration of the issuer’s credit quality over the next six to twelve months, with the credit quality expected to be materially weaker by the end of the designated time horizon.

Individual Bond recommendations:

BUY: Indicates likely to outperform its iBoxx subsector by 5% or more
HOLD: Indicates likely to be within 5% of the performance of its iBoxx subsector
SELL: Indicates likely to underperform its iBoxx subsector by 5% or more

Individual CDS recommendations:

SG Credit research evaluates its expectation of how the 5 year CDS is going to perform vis-à-vis its sector.

SELL: CDS spreads should outperform its iTraxx sector performance
NEUTRAL: CDS spreads should perform in line with its iTraxx sector performance
BUY: CDS spreads should underperform its iTraxx sector performance

Sector weightings:

OVERWEIGHT: Sector spread should outperform its iBoxx corporate index
NEUTRAL: Sector spread should perform in line with its iBoxx corporate index
UNDERWEIGHT: Sector spread should underperform its iBoxx corporate index

All pricing information included in this report is as of market close, unless otherwise stated.

CONFLICTS OF INTEREST

This research contains the views, opinions and recommendations of Société Générale (SG) credit research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental credit opinions and recommendations contained in credit sector or company research reports and from the views and opinions of other departments of SG and its affiliates. Credit research analysts and/or strategists routinely consult with SG sales and trading desk personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of a specific fixed income security or financial instrument, sector or other asset class. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, trading desk and firm revenues and competitive factors. As a general matter, SG and/or its affiliates normally make a market and trade as principal in fixed income securities discussed in research reports.

IMPORTANT DISCLOSURES

European Investment Bank is acting as a joint lead manager in European Investment Bank’s bond issue tap (XS1280834992).
European Investment Bank acted as joint lead manager in EIB’s bond issue (10yr).
European Investment Bank is acting as joint bookrunner in European investment Bank’s bond issue (TAP XS1023039545 15/05/2014).
KFW acted as co-lead-manager in KFW’s bond issue (USD, 3yr).
KFW acted as a member of the selling group for KFW’s bond issue (3yr).

SG or its affiliates had an investment banking client relationship during the past 12 months with European Investment Bank, KFW, SG or its affiliates have received compensation for investment banking services in the past 12 months from European Investment Bank, KFW. SG or its affiliates managed or co-managed in the past 12 months a public offering of securities of European Investment Bank, KFW. SG received compensation for products and services other than investment banking services in the past 12 months from European Investment Bank, KFW.
FOR DISCLOSURES PERTAINING TO COMPREHEND REPORTS OR RECOMMENDATIONS OR ESTIMATES MADE ON SECURITIES OTHER THAN THE PRIMARY SUBJECT OF THIS RESEARCH REPORT, PLEASE VISIT OUR GLOBAL RESEARCH DISCLOSURE WEBSITE AT http://www.sgresearch.com/compliance.rha or call +1 (212),278.6000 in the U.S.

IMPORTANT DISCLAIMER: The information herein is not intended to be an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities and has been obtained from, or is based upon, sources believed to be reliable but is not guaranteed as to accuracy or completeness. Material contained in this report satisfies the regulatory provisions concerning independent investment research as defined in MiFID. Information concerning conflicts of interest and SG’s management of such conflicts is contained in the SG’s Policies for Managing Conflicts of Interests in Connection with Investment Research which is available at https://www.sgresearch.com/Content/Compliance/Compliance.aspx. SG does, from time to time, deal in, trade in, profit from, hold, act as market-makers or advisers, brokers or bankers in relation to the securities, or derivatives thereof, of persons, firms or entities mentioned in this document and may be represented on the board of such persons, firms or entities. SG does, from time to time, act as a principal trader in equities or debt securities that may be referred to in this report and may hold equity or debt securities positions. Employees of SG, or individuals connected to them, may from time to time have a position in or hold any of the investments or related investments mentioned in this document. SG is under no obligation to disclose or take account of this document when advising or dealing with or on behalf of customers. The views of SG reflected in this document may change without notice. In addition, SG may issue other reports that are inconsistent with, and reach different conclusions from, the information presented in this report and is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. To the maximum extent possible at law, SG does not accept any liability whatsoever arising from the use of the material or information contained herein. This research document is not intended for use by or targeted to retail customers. Should a retail customer obtain a copy of this report he/she should not base his/her investment decisions solely on the basis of this document and must seek independent financial advice.

The financial instruments discussed in this report may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein. The price of financial instruments may fluctuate, and investors may receive a positive or negative effect on the price of such securities or financial instruments, and investors in securities such as ADRs effectively assume this risk. SG does not provide any tax advice. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. Investments in general, and derivatives in particular, involve numerous risks, including, among others, market, counterparty default and liquidity risk. Trading in options involves additional risks and is not suitable for all investors. An option may become worthless by its expiration date, as it is a depreciating asset. Option ownership could result in significant loss or gain, especially for options of uncovered positions. Prior to buying or selling an option, investors must review the “Characteristics and Risks of Standardized Options” at http://www.optionsclearing.com/about/publications/character-risks.jsp or from your SG representative. Analysis of option trading strategies does not consider the cost of commissions. Supporting documentation for options trading strategies is available upon request.

Notice to French Investors: This publication is issued in France by or through Société Générale (“SG”) which is authorised and supervised by the Autorité de Contrôle Prudentiel and de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers (AMF).

Notice to U.K. Investors: Société Générale is a French credit institution (bank) authorised by the Autorité de Contrôle Prudentiel (the French Prudential Control Authority) and the Prudential Regulation Authority and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority. Details about the extent of our authorisation and regulation by the Prudential Regulation Authority, and regulation by the Financial Conduct Authority are available from us on request.

Notice to Swiss Investors: This document is provided in Switzerland by or through Société Générale Paris, Zürich Branch, and is provided only to accredited investors, as defined in article 10 of the Swiss Collective Investment Scheme Act (“CISA”) and related provisions of the Collective Investment Scheme Ordinance and in strict compliance with applicable Swiss law and regulations. The products mentioned in this document may not be suitable for all types of investors. This document is based on the Directives on the Independence of Financial Research issued by the Swiss Banks Association (SBA) in January 2008.

Notice to Swiss Investors: This document has been issued in Poland by Société Générale S.A. Oddział w Polsce (“the Branch”) with its registered office in Warsaw (Poland) at 111 Marszałkowska St. The Branch is supervised by the Polish Financial Supervision Authority and the National Bank of Poland. This report is addressed to financial institutions only, as defined in the Act on trading in financial instruments. The Branch certifies that this document has been elaborated with due diligence and care.

Notice to U.S. Investors: For purposes of SEC Rule 15a-6, SG Americas Securities LLC (“SGAS”) takes responsibility for this research report. This report is intended for institutional investors only. Any person or entity wishing to discuss this report or effect transactions in any security discussed herein should do so with or through SGAS, a U.S. registered broker-dealer, futures commission merchant (FCM) and swap dealer. SGAS is a member of FINRA, NYSE, NFA and SIPC and its registered address is 245 Park Ave, 6th Floor, New York, NY, 10167. (212) 278-6000.

Notice to Canadian Investors: This document is for information purposes only and is intended for use by Permitted Clients, as defined under National Instrument 31-103, Accredited Investors, as defined under National Instrument 45-106, Accredited Counterparties as defined under the Derivatives Act (Québec) and “Qualified Parties” as defined under the ASC, BCSC, SFSC and NBSC Orders.

Notice to Singapore Investors: This document is provided in Singapore by or through Société Générale (“SG”), Singapore Branch and is provided only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289. Recipients of this document are to contact Société Générale, Singapore Branch in respect of any matters arising from, or in connection with, the document. If you are an accredited investor or expert investor, please be informed that in SG’s dealings with you, SG is relying on the following exemptions to the Financial Advisers Act, Cap. 110 (“FAA”): (1) the exemption in Regulation 33 of the Financial Advisers Regulations (“FAR”), which exempts SG from complying with Section 25 of the FAA on disclosure of product information to clients; (2) the exemption set out in Regulation 34 of the FAR, which exempts SG from complying with Section 27 of the FAA on recommendations; and (3) the exemption set out in Regulation 35 of the FAR, which exempts SG from complying with Section 36 of the FAA on disclosure of certain interests in securities.

Notice to Hong Kong Investors: This report is distributed in Hong Kong by Société Générale, Hong Kong Branch which is licensed by the Securities and Futures Commission of Hong Kong under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”). This document does not constitute a solicitation or an offer of securities or an invitation to the public within the meaning of the SFO. This report is to be circulated only to “professional investors” as defined in the SFO.

Notice to Japanese Investors: This document is distributed by Société Générale Securities (North Pacific) Ltd., Tokyo Branch, which is regulated by the Financial Services Agency of Japan. This document is intended only for the Specified Investors, as defined by the Financial Instruments and Exchange Law in Japan and only for those people to whom it is sent directly by Société Générale Securities (North Pacific).
Covered bonds Special

Pacific) Ltd., Tokyo Branch, and under no circumstances should it be forwarded to any third party. The products mentioned in this report may not be eligible for sale in Japan and they may not be suitable for all types of investors.

**Notice to Korean Investors:** This report is distributed in Korea by SG Securities Korea Co., Ltd which is regulated by the Financial Supervisory Service and the Financial Services Commission.

**Notice to Australian Investors:** Societe Generale is exempt from the requirement to hold an Australian financial services licence (AFSL) under the Corporations Act 2001 (Cth) in respect of financial services, in reliance on ASIC Class Order 03/8240, a copy of which may be obtained at the web site of the Australian Securities and Investments Commission, http://www.asic.gov.au. The class order exempts financial services providers with a limited connection to Australia from the requirement to hold an AFSL where they provide financial services only to wholesale clients in Australia on certain conditions. Financial services provided by Societe Generale may be regulated under foreign laws and regulatory requirements, which are different from the laws applying in Australia.

http://www.sgciib.com. Copyright: The Société Générale Group 2015. All rights reserved.

This publication may not be reproduced or redistributed in whole in part without the prior consent of SG or its affiliates.